Wechselwirkungen · Ambrisentan Viatris (previously Ambrisentan Mylan)
Ambrisentan Viatris 5 mg film-coated tablets Ambrisentan Viatris 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-143901 · Präparat HOS-099068
The efficacy and safety of ambrisentan when co-administered with other treatments for PAH (e.g. prostanoids and soluble guanylate cyclase stimulators) has not been specifically studied in controlled clinical trials in PAH patients (see section 5.1). No specific drug-drug interactions with soluble guanylate cyclase stimulators or prostanoids are anticipated based on the known biotransformation data (see section 5.2). However, no specific drug-drug interactions studies have been conducted with these active substances. Therefore, caution is recommended in the case of co-administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-03T10:38:00Z · SHA-256 290de251ad262f2e675eecabe30cc2d4db2636bd07a4743908e89f857293d354 · Passage dadceb10d853c6c55c0a6ffe61e78a7b5011c616372ae4d1575077f94ef668c3 · Zeichen 1955–2544 im Abschnitt